Recent Press Releases

European Medicines Agency reviews hypothesis on Pandemrix and development of narcolepsy

European Medicines Agency reviews hypothesis on Pandemrix and development of narcolepsy No new concerns for Pandemrix or other vaccines on the basis of available evidence The European Medicines...

Novavax Reports Positive Top-Line Results from Two Phase 1 Trials of Pandemic Influenza Vaccine

Novavax Reports Positive Top-Line Results from Two Phase 1 Trials of Pandemic Influenza Vaccine • Vaccine candidates met safety and immunogenicity endpoints in both trials • Trials' results...

Sanofi Pasteur Announces Application for New Four-Strain Influenza Vaccine Accepted by FDA for Review

Sanofi Pasteur Announces Application for New Four-Strain Influenza Vaccine Accepted by FDA for Review - CDC analysis of 10 influenza seasons indicates use of a four-strain vaccine could have...

Sanofi Pasteur MSD To Commercialise New 6-in-1 Paediatric Vaccine in European Markets

Sanofi Pasteur MSD To Commercialise New 6-in-1 Paediatric Vaccine in European Markets Vaccine submitted to European Medicines Agency for licence review Lyon: 18th October 2012 – Sanofi Pasteur...

Novavax Reports Positive Top-Line Results from Two Phase 1 Trials of Pandemic Influenza Vaccine

Novavax Reports Positive Top-Line Results from Two Phase 1 Trials of Pandemic Influenza Vaccine • Vaccine candidates met safety and immunogenicity endpoints in both trials • Trials' results...

Genticel announces positive data from its phase I trial in women infected with high-risk HPV before appearance of cervical lesions

Genticel announces positive data from its phase I trial in women infected with high-risk HPV before appearance of cervical lesions Paris, France, October 18, 2012 – Genticel, a...

11 Oct 2012 - Voluntary recall of six batches of Infanrix hexa®

11 Oct 2012 - Voluntary recall of six batches of Infanrix hexa® GSK is working with the Therapeutic Goods Administration (TGA) to voluntarily recall for quality reasons 6 batches of Infanrix hexa...

Immunovaccine Reports Positive Interim Results from Phase I Study of Ovarian Cancer Vaccine Candidate, DPX-Survivac

Immunovaccine Reports Positive Interim Results from Phase I Study of Ovarian Cancer Vaccine Candidate, DPX-Survivac All Patients Treated to Date with Vaccine Therapy Produced Targeted, Dose- Related...

GENOCEA CLOSES $30 MILLION IN SERIES C FINANCING

GENOCEA CLOSES $30 MILLION IN SERIES C FINANCING The Bill & Melinda Gates Foundation and CVF join as new investors Cambridge, MA, October 10, 2012—Genocea Biosciences, Inc., a...

Aeras Signs Agreement with GSK to Jointly Advance TB Vaccine

Aeras Signs Agreement with GSK to Jointly Advance TB Vaccine Phase IIb Proof of Concept Trial Planned for Kenya, India and South Africa Rockville, MD, USA (October 10, 2012) – Aeras announces...

Vaxxas Initiates Program With Merck to Optimize Delivery of Next Generation Vaccines Utilizing Novel Mechanism for Immune System Activation

Vaxxas Initiates Program With Merck to Optimize Delivery of Next Generation Vaccines Utilizing Novel Mechanism for Immune System Activation Collaboration to Evaluate, Develop and Commercialize...

Pfizer Announces Top-Line Results Of Prevenar 13® Phase 3 Trial In Adults 18 To 49 Years Of Age

Pfizer Announces Top-Line Results Of Prevenar 13® Phase 3 Trial In Adults 18 To 49 Years Of Age Data Support EU Regulatory Filing and Planned Worldwide Regulatory Filings For This Age Group NEW...

GeoVax Awarded $1.9 Million Grant by US Government for HIV/AIDS Vaccine Program

GeoVax Awarded $1.9 Million Grant by US Government for HIV/AIDS Vaccine Program Financial Support for Development of Clade C Vaccine ATLANTA, GA -- 10/01/12 -- GeoVax Labs, Inc. (OTCQB: GOVX), an...

Dalton and University of Guelph Collaborate in Anti-TB Vaccine Development

Dalton and University of Guelph Collaborate in Anti-TB Vaccine Development Dalton and University of Guelph are collaborating on the development of an anti-tuberculosis (TB) vaccine. The vaccine is...

Vaccines to Provide a Major Cash Injection for Indian Biopharmaceuticals

Vaccines to Provide a Major Cash Injection for Indian Biopharmaceuticals Concerns regarding the emergence of bioterrorism and Severe Acute Respiratory Syndrome (SARS), in addition to the search for...

GenVec Enters Into $3.5 Million Contract With Naval Medical Research Center To Advance Malaria Program

GenVec Enters Into $3.5 Million Contract With Naval Medical Research Center To Advance Malaria Program GAITHERSBURG, Md., Oct. 2, 2012 -- GenVec, Inc. (Nasdaq: GNVC) announced today that it has...

Sinovac Awarded Tenders in Beijing and Shanghai to Supply Inactivated Hepatitis A Vaccine Healive® Under Expanded Immunization Program

Sinovac Awarded Tenders in Beijing and Shanghai to Supply Inactivated Hepatitis A Vaccine Healive® Under Expanded Immunization Program BEIJING, Sept. 25, 2012 -- Sinovac Biotech Ltd. (Nasdaq:...

PSIOXUS LAUNCHES PHASE I/II CLINICAL TRIAL OF ONCOLYTIC VACCINE WITH DOSING OF PATIENT WITH METASTATIC CANCER

PSIOXUS LAUNCHES PHASE I/II CLINICAL TRIAL OF ONCOLYTIC VACCINE WITH DOSING OF PATIENT WITH METASTATIC CANCER 'Evolve' Study Will Assess Safety and Tolerability of Unique Anti-Cancer Agent, ColoAd1...

Medicago and Philip Morris Products Sign Commercial Agreement for Influenza Vaccines in China

Medicago and Philip Morris Products Sign Commercial Agreement for Influenza Vaccines in China QUEBEC CITY, Sept. 25, 2012 -- Medicago to receive up to US$12 million in upfront and milestone payments...

ATRECA, INC. RECEIVES $6 MILLION INVESTMENT TO APPLY IMMUNE REPERTOIRE CAPTURETM TECHNOLOGY TO PREVENT AND TREAT HUMAN INFECTIOUS DISEASES

ATRECA, INC. RECEIVES $6 MILLION INVESTMENT TO APPLY IMMUNE REPERTOIRE CAPTURETM TECHNOLOGY TO PREVENT AND TREAT HUMAN INFECTIOUS DISEASES — Investment and additional project funding from the...